Kimberly is Founder and CEO of KKH Advisors, a life sciences and digital health strategic communications firm. She was previously Senior Director at FTI Consulting, Life Sciences and Healthcare, Capital Markets, where she advised a broad range of clients from Fortune 500 to early-stage companies on business transformation, corporate and executive positioning, crisis and issues management, and financial communications with a focus on IPO readiness.
Prior to FTI Consulting (NYSE: FCN), a global business advisory firm, she was Global Editor at BioPharm Insight, a business intelligence product launched by the Financial Times Group. She started her career as an M&A reporter in Hong Kong covering Asia-Pacific healthcare, and transferred to New York to cover US pharmaceuticals in 2007.
Kimberly is a frequent guest speaker at major industry conferences, including BIO International, Prix Galien Forum, Biotech Showcase, FierceBiotech, Davis Polk IPO Seminars, and others.
Prior to FTI Consulting (NYSE: FCN), a global business advisory firm, she was Global Editor at BioPharm Insight, a business intelligence product launched by the Financial Times Group. She started her career as an M&A reporter in Hong Kong covering Asia-Pacific healthcare, and transferred to New York to cover US pharmaceuticals in 2007.
Kimberly is a frequent guest speaker at major industry conferences, including BIO International, Prix Galien Forum, Biotech Showcase, FierceBiotech, Davis Polk IPO Seminars, and others.
Speaking In
11:00 AM - 12:00 PM (PDT)
Tuesday, June 14
Recent collaborations and financing deals involving small-mid biotechs and big pharmaceutical firms…
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
